Table 1.
Clinical and demographic features in patients with COVID-19 infection.
| No. of patients (n = 108) | |
|---|---|
| Age (mean ± SD) | 51.2 ± 17.7 |
| Sex (M/F) | 70/38 (64.8%/35.2%) |
| Symptomatology | |
| Fever | 82 (75.9%) |
| Cough | 60 (55.6%) |
| Dyspnoea | 57 (52.8%) |
| Sore throat | 12 (11.1%) |
| Fatigue | 12 (11.1%) |
| Chest pain | 9 (8.3%) |
| Headache | 8 (7.4%) |
| Rhinorrhoea | 7 (6.5%) |
| Diarrhoea | 7 (6.5%) |
| Altered sensorium | 5 (4.6%) |
| Myalgias | 4 (3.7%) |
| Anorexia | 3 (2.8%) |
| Pain abdomen | 3 (2.8%) |
| Duration of symptoms (mean ± SD) | 3.9 ± 2.4 |
| Presence of co-morbidities | 60 (55.5%) |
| Co-morbidities | |
| Hypertension | 41 (38%) |
| Diabetes Mellitus | 35 (32.4%) |
| Diabetes status (controlled/uncontrolled) | 11 (31.4%)/24 (68.6%) |
| Cardiovascular disease | 14 (13%) |
| Dyslipidaemia | 6 (5.6%) |
| Heart Failure | 1 (0.9%) |
| Chronic lung diseases: | 14 (13%) |
| Chronic obstructive pulmonary disease | 6 (5.6%) |
| Asthma | 3 (2.8%) |
| Post-tubercular sequalae | 3 (2.8%) |
| Interstitial Lung Disease | 1 (0.9%) |
| Bronchiectasis | 1 (0.9%) |
| Chronic Kidney Disease | 9 (8.3%) |
| Malignancy | 3 (2.8%) |
| Smoking | 10 (9.3%) |
| Use of ACEi/ARBs | 13 (12%) |
| Duration of hospital stay | 8.7 ± 6.1 days |
| Time to COVID-19 negativity | 7.04 ± 3.9 days |
ACEi: angiotensin converting enzyme inhibitor; ARBs: Angiotensin receptor blockers; COVID-19: coronavirus disease 2019; F: female; M: male; No.: number; SD: standard deviation.